Esperion Therapeutics ESPR Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's debt issuance cost amortization?
- Esperion Therapeutics (ESPR) reported debt issuance cost amortization of $589K in Q1 2026.
- How has Esperion Therapeutics's debt issuance cost amortization changed year-over-year?
- Esperion Therapeutics's debt issuance cost amortization decreased by 15.7% year-over-year, from $699K to $589K.
- What is the long-term trend for Esperion Therapeutics's debt issuance cost amortization?
- Over 4 years (2021 to 2025), Esperion Therapeutics's debt issuance cost amortization has grown at a 16.7% compound annual growth rate (CAGR), from $1.62M to $3.01M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).